Skip to main content
Caplight Logo









Gate2Brain

Gate2Brain

Private
BarcelonaHealthcare & Life Scienceshttps://gate2brain.com/

Last Round

Early Funding

Jun 16, 2026

Est. Valuation

$26.74M

Total Funding Raised

$6.02M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Gate2Brain is a biotechnology company that has developed a peptide-based technology platform for delivering therapeutics across biological barriers, such as the blood-brain barrier.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

blood-brain barrier deliverydrug delivery platformBBB deliverypeptide shuttleCNS drug deliverybrain shuttlepeptide drug conjugatecentral nervous systemCNSbiologic drug deliverydrug licensingpediatric brain tumorsco-development agreementsDIPG treatmentneurodegenerative disorders

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Gate2Brain Comparables

Compare Gate2Brain with similar companies based on industry and business-model similarity.

Gate2Brain comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Key2Brain
85%
Vect-Horus
83%
D2B3
82%

Gate2Brain Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingJun 16, 2026
Convertible DebtNov 6, 2024
GrantDec 21, 2022
GrantJan 13, 2022
GrantDec 22, 2021
Pre Seed
Jul 9, 2020

Key People

Founding team and executive leadership

Meritxell Teixido

CEO CSO

Executive Team

Gate2Brain Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2026

    Monthly visitors grew 97% MoM.

  • Jun 20, 2026

    Monthly visitors increased 52% MoM, reaching 1.2K.

Gate2Brain Filings

Explore SEC and related filing metadata, where available.

Gate2Brain filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Gate2Brain's valuation, stock price, and market status.

Is Gate2Brain a public or private company?

Gate2Brain is a private company.

What is the current stock price of Gate2Brain?

Gate2Brain is a private company with no public stock price. No recent secondary market data is available.

How much is Gate2Brain worth (valuation)?

Gate2Brain's valuation is estimated at $26.7M based on funding round data.

Can I buy Gate2Brain stock?

Gate2Brain shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Gate2Brain's last funding round?

Gate2Brain's most recent funding round was Early Funding on June 16, 2026.

Who are the main investors in Gate2Brain?

Key investors in Gate2Brain include European Innovation Council, Fundación la Caixa, BStartup Health, University of Barcelona, Center for Technological Development and Innovation.

Will Gate2Brain IPO soon?

No public IPO plans have been announced for Gate2Brain.

How can I track Gate2Brain secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Gate2Brain's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBarcelona
Employee Range11
Year Founded2020
Last FundingJun 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?